Attendee search 

College Hill Life Sciences is a strategic communications consultancy with over two decades of experience in advising life science organisations worldwide. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting PR, IR and design solutions that showcase each company, product or technology.

We have earned a formidable reputation for incisive board-level communications counsel. Our deep understanding of the needs and drivers of the life science industry and our entrepreneurial approach comes from our teams’ backgrounds in executive management, R&D, Government, sales & marketing, journalism and finance within the life science sector.

With a track record of delivering truly creative programmes, we focus on enhancing the value proposition for companies seeking investment, partnerships or customers. We form long-standing relationships with our clients in biotech, pharma, medical device and diagnostic companies as well as companies that enable scientific research through the supply of enabling technologies and services. We also advise venture investors and service providers.

Our approach is personal, professional and flexible, with value for money as a principle. We are passionate about our clients’ and about making a difference.

Our globally integrated and dedicated life sciences team serve clients around the world from our bases in London, Manchester, Munich, Boston and Sydney.

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis.

The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of Ireland’s leading academic institution with a core focus on immunology research. Opsona's lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers. The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.

The Company is supported by an international venture consortium including Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and Enterprise Ireland. Further information is available at http://www.opsona.com/.

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.